Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yucai Wang, Melissa C. Larson, Anita Kumar, Brian T Hill, David Alan Bond, Brad S. Kahl, Alexey Valeryevich Danilov, Reid Merryman, Natalie Sophia Grover, Aung M. Tun, Sabarish Ram Ayyappan, Georgios Pongas, Craig Anthony Portell, Javier Munoz, Patrick Michael Reagan, Muhamad Alhaj Moustafa, Priyanka Avinash Pophali, Irl Brian Greenwell, Jonathon Brett Cohen, Peter Martin
Institutions: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, The Ohio State University, Washington University in St. Louis, City Of Hope National Medical Center, City of Hope, Dana-Farber Cancer Institute, University of North Carolina at Chapel Hill, The University of Kansas Cancer Center, University of Iowa, University of Miami, University of Virginia, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), University of Rochester Medicine, Mayo Clinic in Florida, University of Wisconsin Carbone Cancer Center, Medical University of South Carolina, Emory University, Cornell University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4400109258